PDF herunterladen
CC BY-NC-ND 4.0 · Thromb Haemost 2018; 118(02): 298-308
DOI: 10.1160/TH17-04-0249
Coagulation and Fibrinolysis
Schattauer GmbH Stuttgart

A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor

Tara M. Stanne
1   Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
,
Maja Olsson
1   Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
,
Erik Lorentzen
2   Bioinformatics Core Facility, University of Gothenburg, Gothenburg, Sweden
,
Annie Pedersen
1   Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
,
Anders Gummesson
1   Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
,
Ann Gils
3   Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Brussels, Belgium
,
Katarina Jood
4   Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
,
Gunnar Engström
5   Department of Clinical Sciences, Lund University, Lund, Sweden
,
Olle Melander
5   Department of Clinical Sciences, Lund University, Lund, Sweden
,
Paul J. Declerck
3   Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Brussels, Belgium
,
Christina Jern
1   Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
› Institutsangaben
Weitere Informationen

Publikationsverlauf

10. April 2017

10. November 2017

Publikationsdatum:
29. Januar 2018 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Thrombin-activatable fibrinolysis inhibitor (TAFI) plays a central role in haemostasis, and plasma TAFI concentrations are heritable. Candidate gene studies have identified several variants within the gene encoding TAFI, CPB2, that explain part of the estimated heritability. Here, we describe an exploratory genome-wide association study to identify novel variants within and outside of the CPB2 locus that influence plasma concentrations of intact TAFI and/or the extent of TAFI activation (measured by released TAFI activation peptide, TAFI-AP) amongst 3,260 subjects from Southern Sweden. We also explored the role of rare variants on the HumanExome BeadChip. We confirmed the association with previously reported common variants in CPB2 for both intact TAFI and TAFI-AP, and discovered novel associations with variants in putative CPB2 enhancers. We identified a gene-based association with intact TAFI at CPB2 (P SKAT-O = 2.8 × 10−8), driven by two novel rare nonsynonymous single nucleotide polymorphisms (SNPs; I420N and D177G). Carriers of the rare variant of D177G (rs140446990; MAF 0.2%) had lower intact TAFI and TAFI-AP concentrations compared with non-carriers (intact TAFI, geometric mean 53 vs. 78%, P T-test = 5 × 10−7; TAFI-AP 63 vs. 99%, P T-test = 7.2 × 10−4). For TAFI-AP, we identified a genome-wide significant association at an intergenic region of chromosome 3p14.1 and five gene-based associations (all P SKAT-O < 5 × 10−6). Using well-characterized assays together with a genome-wide association study and a rare-variant approach, we verified CPB2 to be the primary determinant of TAFI concentrations and identified putative secondary loci (candidate variants and genes) associated with intact TAFI and TAFI-AP that require independent validation.

Keywords

thrombin-activatable fibrinolysis inhibitor - fibrinolysis inhibitors - plasma levels - genome-wide association study

Financial Support

The present study was supported by the Swedish Research Council and grants from the Swedish state (ALF), the Swedish Heart-Lung Foundation and the Swedish Stroke Association. The National Institute of Neurological Disorders and Stroke (NINDS) funded the genotyping of patients included in the SiGN study. PI, Steven Kittner.


Supplementary Material

 

  • References

  • 1 Swaisgood CM, Schmitt D, Eaton D, Plow EF. In vivo regulation of plasminogen function by plasma carboxypeptidase B. J Clin Invest 2002; 110 (09) 1275-1282
    CrossrefPubMedGoogle Scholar
  • 2 Boffa MB, Koschinsky ML. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem 2007; 40 (07) 431-442
    CrossrefPubMedGoogle Scholar
  • 3 Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271 (28) 16603-16608
    CrossrefPubMedGoogle Scholar
  • 4 Mao SS, Cooper CM, Wood T, Shafer JA, Gardell SJ. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans. J Biol Chem 1999; 274 (49) 35046-35052
    CrossrefPubMedGoogle Scholar
  • 5 Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273 (42) 27176-27181
    CrossrefPubMedGoogle Scholar
  • 6 Marx PF, Dawson PE, Bouma BN, Meijers JC. Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry 2002; 41 (21) 6688-6696
    CrossrefPubMedGoogle Scholar
  • 7 Franco RF, Fagundes MG, Meijers JC. , et al. Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 2001; 86 (05) 510-517
    PubMedGoogle Scholar
  • 8 van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95 (09) 2855-2859
    CrossrefPubMedGoogle Scholar
  • 9 Santamaría A, Martínez-Rubio A, Borrell M, Mateo J, Ortín R, Fontcuberta J. Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level. Haematologica 2004; 89 (07) 880-881
    PubMedGoogle Scholar
  • 10 Schroeder V, Wilmer M, Buehler B, Kohler HP. TAFI activity in coronary artery disease: a contribution to the current discussion on TAFI assays. Thromb Haemost 2006; 96 (02) 236-237
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 11 Ladenvall C, Gils A, Jood K, Blomstrand C, Declerck PJ, Jern C. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. Arterioscler Thromb Vasc Biol 2007; 27 (04) 955-962
    CrossrefPubMedGoogle Scholar
  • 12 Leebeek FW, Goor MP, Guimaraes AH. , et al. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 2005; 3 (10) 2211-2218
    CrossrefPubMedGoogle Scholar
  • 13 Montaner J, Ribó M, Monasterio J, Molina CA, Alvarez-Sabín J. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 2003; 34 (04) 1038-1040
    CrossrefPubMedGoogle Scholar
  • 14 Chetaille P, Alessi MC, Kouassi D, Morange PE, Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 2000; 83 (06) 902-905
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 15 Ariëns RAS, de Lange M, Snieder H, Boothby M, Spector TD, Grant PJ. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lancet 2002; 359 (9307): 667-671
    CrossrefPubMedGoogle Scholar
  • 16 Bladbjerg EM, de Maat MPM, Christensen K, Bathum L, Jespersen J, Hjelmborg J. Genetic influence on thrombotic risk markers in the elderly--a Danish twin study. J Thromb Haemost 2006; 4 (03) 599-607
    CrossrefPubMedGoogle Scholar
  • 17 Peetz D, Victor A, Adams P. , et al. Genetic and environmental influences on the fibrinolytic system: a twin study. Thromb Haemost 2004; 92 (02) 344-351
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 18 Sabater-Lleal M, Buil A, Souto JC. , et al. A genome-wide exploration suggests an oligogenic model of inheritance for the TAFI activity and its antigen levels. Hum Genet 2008; 124 (01) 81-88
    CrossrefPubMedGoogle Scholar
  • 19 Trégouet DA, Aubert H, Henry M. , et al. Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms. Hum Genet 2001; 109 (02) 191-197
    CrossrefPubMedGoogle Scholar
  • 20 Warren DM, Cole SA, Dyer TD. , et al. A locus on chromosome 13 influences levels of TAFI antigen in healthy Mexican Americans. Hum Biol 2006; 78 (03) 329-339
    CrossrefPubMedGoogle Scholar
  • 21 Brouwers GJ, Vos HL, Leebeek FW. , et al. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 2001; 98 (06) 1992-1993
    CrossrefPubMedGoogle Scholar
  • 22 Henry M, Aubert H, Morange PE. , et al. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001; 97 (07) 2053-2058
    CrossrefPubMedGoogle Scholar
  • 23 Zhao L, Morser J, Bajzar L, Nesheim M, Nagashima M. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms. Thromb Haemost 1998; 80 (06) 949-955
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 24 Gils A, Alessi MC, Brouwers E. , et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23 (06) 1122-1127
    CrossrefPubMedGoogle Scholar
  • 25 Guimarães AH, van Tilburg NH, Vos HL, Bertina RM, Rijken DC. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol 2004; 124 (05) 659-665
    CrossrefPubMedGoogle Scholar
  • 26 Ceresa E, Brouwers E, Peeters M, Jern C, Declerck PJ, Gils A. Development of ELISAs measuring the extent of TAFI activation. Arterioscler Thromb Vasc Biol 2006; 26 (02) 423-428
    CrossrefPubMedGoogle Scholar
  • 27 Söderholm M, Almgren P, Jood K. , et al. Exome array analysis of ischaemic stroke: results from a southern Swedish study. Eur J Neurol 2016; 23 (12) 1722-1728
    CrossrefPubMedGoogle Scholar
  • 28 Jood K, Ladenvall C, Rosengren A, Blomstrand C, Jern C. Family history in ischemic stroke before 70 years of age: the Sahlgrenska Academy Study on Ischemic Stroke. Stroke 2005; 36 (07) 1383-1387
    CrossrefPubMedGoogle Scholar
  • 29 Li C, Engström G, Hedblad B, Berglund G, Janzon L. Risk factors for stroke in subjects with normal blood pressure: a prospective cohort study. Stroke 2005; 36 (02) 234-238
    CrossrefPubMedGoogle Scholar
  • 30 NINDS Stroke Genetics Network (SiGN); International Stroke Genetics Consortium (ISGC). Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study. Lancet Neurol 2016; 15 (02) 174-184
    CrossrefPubMedGoogle Scholar
  • 31 Goldstein JI, Crenshaw A, Carey J. , et al; Swedish Schizophrenia Consortium; ARRA Autism Sequencing Consortium. zCall: a rare variant caller for array-based genotyping: genetics and population analysis. Bioinformatics 2012; 28 (19) 2543-2545
    CrossrefPubMedGoogle Scholar
  • 32 McCarthy S, Das S, Kretzschmar W. , et al; Haplotype Reference Consortium. A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet 2016; 48 (10) 1279-1283
    CrossrefPubMedGoogle Scholar
  • 33 Delaneau O, Howie B, Cox AJ, Zagury JF, Marchini J. Haplotype estimation using sequencing reads. Am J Hum Genet 2013; 93 (04) 687-696
    CrossrefPubMedGoogle Scholar
  • 34 Lee S, Emond MJ, Bamshad MJ. , et al; NHLBI GO Exome Sequencing Project—ESP Lung Project Team. Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. Am J Hum Genet 2012; 91 (02) 224-237
    CrossrefPubMedGoogle Scholar
  • 35 Lonsdale J, Thomas J, Salvatore M. , et al; GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet 2013; 45 (06) 580-585
    CrossrefPubMedGoogle Scholar
  • 36 Veyrieras JB, Kudaravalli S, Kim SY. , et al. High-resolution mapping of expression-QTLs yields insight into human gene regulation. PLoS Genet 2008; 4 (10) e1000214
    CrossrefPubMedGoogle Scholar
  • 37 Westra H-J, Peters MJ, Esko T. , et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat Genet 2013; 45 (10) 1238-1243
    CrossrefPubMedGoogle Scholar
  • 38 Frère C, Morange PE, Saut N. , et al. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. Thromb Haemost 2005; 94 (02) 373-379
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 39 Frère C, Tregouet DA, Morange PE. , et al. Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study. Blood 2006; 108 (05) 1562-1568
    CrossrefPubMedGoogle Scholar
  • 40 Biswas A, Ranjan R, Meena A. , et al. TAFI antigen level variability in young healthy Asian Indians; first report from Asia. Clin Biochem 2008; 41 (09) 750-753
    CrossrefPubMedGoogle Scholar
  • 41 Boffa MB, Maret D, Hamill JD. , et al. Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis. Blood 2008; 111 (01) 183-189
    CrossrefPubMedGoogle Scholar
  • 42 Maret D, Boffa MB, Brien DF, Nesheim ME, Koschinsky ML. Role of mRNA transcript stability in modulation of expression of the gene encoding thrombin activable fibrinolysis inhibitor. J Thromb Haemost 2004; 2 (11) 1969-1979
    CrossrefPubMedGoogle Scholar
  • 43 Morange PE, Tregouet DA, Frere C. , et al; Prime Study Group. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study. J Thromb Haemost 2005; 3 (07) 1503-1510
    CrossrefPubMedGoogle Scholar
  • 44 Boffa MB, Reid TS, Joo E, Nesheim ME, Koschinsky ML. Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B). Biochemistry 1999; 38 (20) 6547-6558
    CrossrefPubMedGoogle Scholar
  • 45 Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277 (02) 1021-1030
    CrossrefPubMedGoogle Scholar
  • 46 Villegas VE, Zaphiropoulos PG. Neighboring gene regulation by antisense long non-coding RNAs. Int J Mol Sci 2015; 16 (02) 3251-3266
    CrossrefPubMedGoogle Scholar
  • 47 Mahajan-Thakur S, Böhm A, Jedlitschky G, Schrör K, Rauch BH. Sphingosine-1-phosphate and its receptors: a mutual link between blood coagulation and inflammation. Mediators Inflamm 2015; 2015: 831059
    PubMedGoogle Scholar
  • 48 Knapp M. Cardioprotective role of sphingosine-1-phosphate. J Physiol Pharmacol 2011; 62 (06) 601-607
    PubMedGoogle Scholar
  • 49 Wei Y, Yemisci M, Kim HH. , et al. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol 2011; 69 (01) 119-129
    CrossrefPubMedGoogle Scholar
  • 50 Zhao Z, Wang R, Huo Z, Li C, Wang Z. Characterization of the anticoagulant and antithrombotic properties of the Sphingosine 1-phosphate mimetic FTY720. Acta Haematol 2017; 137 (01) 1-6
    CrossrefPubMedGoogle Scholar